@article{oai:kanazawa-u.repo.nii.ac.jp:00014091,
 author = {寺島, 健志 and 山下, 竜也 and 荒井, 邦明 and 砂子坂, 肇 and 北原, 征明 and 加賀谷, 尚史 and 水腰, 英四郎 and 本多, 政夫 and 金子, 周一 and Terashima, Takeshi and Yamashita, Tatsuya and Arai, Kuniaki and Sunagozaka, Hajime and Kitahara, Masaaki and Nakagawa, Hidetoshi and Kagaya, Takashi and Mizukoshi, Eishiro and Honda, Masao and Kaneko, Shuichi},
 issue = {12},
 journal = {Hepatology Research},
 month = {Nov},
 note = {Aim: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). However, although there is no proven therapeutic procedure following the termination of sorafenib, hepatic arterial infusion chemotherapy (HAIC) may be a treatment option in advanced HCC. The aim of this study was to evaluate feasibility and efficacy of HAIC for patients with advanced HCC as subsequent therapy. Methods: We retrospectively evaluated 27 consecutive patients with advanced HCC who were treated with HAIC following sorafenib between June 2009 and December 2012 at our hospital. Cisplatin (20 mg/m2 per day) was administered via the hepatic artery for 10 min, prior to the continuous administration of 5-fluorouracil (330 mg/m2 per day) over 24 h from days 1-5 and 8-12 and the s.c. administration of pegylated interferon α-2b (1 μg/kg) on days 1, 8, 15, and 22. A treatment cycle consisted of 28 days of drug administration followed by 14 days of rest. Results: The toxicity profile showed that hematological toxicities were common, and grade 3/4 neutropenia and thrombocytopenia were observed (51.9% and 48.1%, respectively). Five patients (18.5%) experienced device-related complications. No unexpected adverse reactions and no treatmentrelated deaths were observed. Partial response was obtained in eight patients (29.6%), and stable disease was noted in nine patients (33.3%). Median progression-free survival and median survival time from initiation of HAIC were 4.0 and 7.6 months, respectively. Conclusions: Because HAIC was well tolerated and exhibited moderate antitumor activity, it is a potentially useful treatment procedure in patients with advanced HCC even after failure of sorafenib., 金沢大学先進予防医学研究センター / 金沢大学医薬保健研究域医学系},
 pages = {1179--1185},
 title = {Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib},
 volume = {44},
 year = {2014}
}